Cipla consolidated net profit for the quarter ending June 2025 at ₹1291.61 crore was up 10% compared to ₹1175.46 crore in the ...

Cipla posted a 10.3% rise in Q1 profit with stable EBITDA margins and strong gross margin expansion helping offset pressure ...

Cipla share price gain 3% after Q1 earnings beat estimates, with strong margins, India growth, and positive analyst sentiment ...

Cipla is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, ...

As Cipla turns 90, the pharmaceutical giant is reimagining itself as a brand fit for a wellness-driven, digital-first India.

As global demand for next-generation therapies on diabetes and weight loss surges, Indian pharmaceutical companies are ...

Cipla Ltd ( ($IN:CIPLA) ) just unveiled an update. Cipla Ltd announced the opening of a special window for the re-lodgement of transfer requests ...

Biocon and Aurobindo Pharma are identified as facing significant EPS impacts within the generics and biosimilars domain.

The sale of a stake in Cipla Ltd. is in jeopardy as potential buyers have balked at the 1.09 trillion rupee ($13.1 billion) valuation members of the founding family are targeting for the Indian ...

CIPLA Ltd. Annual stock financials by MarketWatch. View the latest CIPLA financial statements, income statements and financial ratios.

India's Cipla (CIPL.NS) said on Saturday that its manufacturing of the COVID-19 remdesivir drug was beginning to catch up with demand after the company sought to boost production amid a massive ...

A decade ago Yusuf Hamied, chairman and managing director of Indian drugmaker Cipla (sales: $1.2 billion), earned the label of “drug pirate” for his cheap knockoffs, notably of expensive AIDS ...